Search

Displaying results 1791 - 1800 of 6076 in total
  1. Drug

    Etranacogene dezaparvovec

    go.drugbank.com/drugs/DB16791
    ApprovedInvestigational

    [L44186] In December 2022, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended etranacogene dezaparvovec be granted marketing authorization for the treatment of severe and moderately … [L44161,L44181] Etranacogene dezaparvovec (Hemgenix, CSL Bering LLC) is a gene therapy for the treatment of hemophilia B that provides a new treatment modality for its patients.

  2. Drug

    Iobenguane sulfate I-123

    go.drugbank.com/drugs/DB09546
    Approved

    Iobenguane sulfate I-123 is a radiopharmaceutical used in gamma-scintigraphy of adrenergically inervated tissues [FDA Label].

  3. Drug

    Doxazosin

    go.drugbank.com/drugs/DB00590
    ApprovedInvestigational

    Doxazosin is an alpha-1 antagonist used for the treatment of benign prostatic hypertrophy (BPH) symptoms and hypertension.

    Categories: Antihypertensive Agents Indicated for Hypertension
  4. Drug

    Brotizolam

    go.drugbank.com/drugs/DB09017
    ApprovedWithdrawn

    Brotizolam is indicated for 2-4 weeks of treatment for severe or debilitating insomnia. … Brotizolam is not approved for sale in the UK, United States or Canada but is sold in the Netherlands, Germany, Spain, Belgium, Austria, Portugal, Israel, Italy and Japan.

  5. Drug

    Nitrite

    go.drugbank.com/drugs/DB12529
    ApprovedWithdrawn

    Nitrite is under investigation for the treatment of Heart Failure.

  6. Drug

    Ammonia

    go.drugbank.com/drugs/DB11118
    ApprovedInvestigational

    The radiolabelled form of ammonia, ammonia N 13, is intravenously administered as a radioactive diagnostic agent for Positron Emission Tomography (PET) imaging of the myocardium to evaluate myocardial

    Mixtures: JACK Smelling Salts for Athletes and Eucalyptus Oil
  7. Drug

    Netupitant

    go.drugbank.com/drugs/DB09048
    ApprovedInvestigational

    Netupitant is an antiemitic drug approved by the FDA in October 2014 for use in combination with palonosetron for the prevention of acute and delayed vomiting and nausea associated with cancer chemotherapy

  8. Drug

    Hyoscyamine

    go.drugbank.com/drugs/DB00424
    ApprovedInvestigational

    [A228713] Hyoscyamine is used for a wide variety of treatments and therapeutics due to its antimuscarinic properties.

    Categories: Drugs for Functional Gastrointestinal Disorders
  9. Drug

    Zilucoplan

    go.drugbank.com/drugs/DB15636
    ApprovedInvestigational

    [L48701] It was also later approved by the EMA on December 4, 2023, as an add-on treatment for the same condition.[L49131] In July 2024, it was approved by Health Canada for the same indication. … [A261841] On October 17, 2023, zilucoplan gained its first FDA approval for the treatment of generalized myasthenia gravis.

  10. Drug

    Dorocubicel

    go.drugbank.com/drugs/DB19448
    Approved

    following myeloablative conditioning in adult patients for whom a suitable donor is not available. … [L54116,L54106] Zemcelpro is the first approved cell therapy for blood cancer patients lacking suitable donor cells.[L54116]